Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators.; UK ProtecT Study Collaborators.; PRACTICAL Consortium., Easton DF, Eeles RA, Kote-Jarai Z.

Br J Cancer. 2016 Apr 12;114(8):945-52.

2.

Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, Mcdonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokołorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Viñuela A, Brown AA; PRACTICAL Consortium.; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative.; Australian Prostate Cancer BioResource.; UK Genetic Prostate Cancer Study Collaborators.; UK ProtecT Study Collaborators., Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z.

Hum Mol Genet. 2015 Oct 1;24(19):5589-602. doi: 10.1093/hmg/ddv203. Epub 2015 May 29.

3.

The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.

Badreldin W, Krell J, Chowdhury S, Harland SJ, Mazhar D, Harding V, Frampton AE, Wilson P, Berney D, Stebbing J, Shamash J.

BJU Int. 2016 Mar;117(3):418-23. doi: 10.1111/bju.13004. Epub 2015 Jun 13.

4.

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).

Nicholson S, Hall E, Harland SJ, Chester JD, Pickering L, Barber J, Elliott T, Thomson A, Burnett S, Cruickshank C, Carrington B, Waters R, Bahl A.

Br J Cancer. 2013 Nov 12;109(10):2554-9. doi: 10.1038/bjc.2013.620. Epub 2013 Oct 29.

5.

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

International Collaboration of Trialists.; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group).; European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group.; Australian Bladder Cancer Study Group.; National Cancer Institute of Canada Clinical Trials Group.; Finnbladder.; Norwegian Bladder Cancer Study Group.; Club Urologico Espanol de Tratamiento Oncologico Group., Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK.

J Clin Oncol. 2011 Jun 1;29(16):2171-7. doi: 10.1200/JCO.2010.32.3139. Epub 2011 Apr 18.

6.

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.

Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology.; UK ProtecT Study Collaborators.; PRACTICAL Consortium., Easton DF.

Nat Genet. 2009 Oct;41(10):1116-21. doi: 10.1038/ng.450. Epub 2009 Sep 20.

7.

Multiple loci on 8q24 associated with prostate cancer susceptibility.

Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, English DR, Dearnaley DP, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Sawyer E, Lophatananon A; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology.; UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators., Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper C, Donovan JL, Hamdy FC, Neal DE, Eeles RA, Easton DF.

Nat Genet. 2009 Oct;41(10):1058-60. doi: 10.1038/ng.452. Epub 2009 Sep 20.

PMID:
19767752
8.

Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.

Kalsi J, Harland SJ, Feneley MR.

Expert Opin Drug Deliv. 2008 Jan;5(1):137-45. Review.

PMID:
18095933
9.

Do all patients with bilateral testis cancer have a hereditary predisposition?

Harland SJ, Rapley EA, Nicholson PW.

Int J Androl. 2007 Aug;30(4):251-5; discussion 255.

PMID:
17705806
10.

18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group.

Huddart RA, O'Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK, Vasey P, Harland SJ, Logue J, Daugaard G, Hain SF, Kirk SJ, MacKewn JE, Stenning SP; NCRI Testis Tumour Clinical Study Group..

J Clin Oncol. 2007 Jul 20;25(21):3090-5.

PMID:
17634488
11.

A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder.

Harland SJ, Kynaston H, Grigor K, Wallace DM, Beacock C, Kockelbergh R, Clawson S, Barlow T, Parmar MK, Griffiths GO; National Cancer Research Institute Bladder Clinical Studies Group..

J Urol. 2007 Sep;178(3 Pt 1):807-13; discussion 813. Epub 2007 Jul 16.

PMID:
17631326
12.

Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group.

Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA, Sokal MP, Joffe JK, Harland SJ, Kirk SJ; National Cancer Research Institute Testis Cancer Clinical Studies Group..

J Clin Oncol. 2007 Apr 10;25(11):1310-5.

PMID:
17416851
13.

Chemotherapy for hormone-resistant prostate cancer: Where are we today?

Buchler T, Harland SJ.

Indian J Urol. 2007 Jan;23(1):55-60. doi: 10.4103/0970-1591.30269.

14.

Electromotive drug delivery and bladder cancer.

Harland SJ.

Lancet Oncol. 2006 Jan;7(1):6-7. No abstract available. Erratum in: Lancet Oncol. 2006 Feb;7(2):105.

PMID:
16389175
15.

A second look at the pT1 G3 bladder tumour.

Harland SJ.

Clin Oncol (R Coll Radiol). 2005 Oct;17(7):498-502. Review.

PMID:
16238136
16.

Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL.

Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ; BAUS Section of Oncology Cancer Registry..

BJU Int. 2005 Aug;96(3):303-7.

17.

Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17).

Dearnaley DP, Fossa SD, Kaye SB, Cullen MH, Harland SJ, Sokal MP, Graham JD, Roberts JT, Mead GM, Williams MV, Cook PA, Stenning SP; MRC Testicular Tumour Working Party..

Br J Cancer. 2005 Jun 20;92(12):2107-13.

18.
19.

Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours.

McNeish IA, Kanfer EJ, Haynes R, Giles C, Harland SJ, Driver D, Rustin GJ, Newlands ES, Seckl MJ.

Br J Cancer. 2004 Mar 22;90(6):1169-75.

20.

Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.

Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ; BAUS Section of Oncology Cancer Registry..

Cancer. 2003 Dec 1;98(11):2362-7.

Supplemental Content

Loading ...
Support Center